A new analysis of 531 participants suggests that miRNA panels may be a promising tool for diagnosing endometrial cancer. The study, a meta-analysis of multiple smaller studies, looked at how well these panels could distinguish between women with and without the disease.
The results showed that miRNA panels had a high diagnostic accuracy. The pooled sensitivity was 0.90, meaning they correctly identified 90% of cancer cases. The pooled specificity was 0.93, meaning they correctly ruled out cancer in 93% of women without the disease. The overall diagnostic odds ratio was 119.50, indicating strong performance.
However, the researchers caution that the studies included had substantial differences (heterogeneity) and methodological limitations. This means the results may not be as reliable as they seem. The findings are promising but not yet ready for routine clinical use.
For now, women concerned about endometrial cancer should talk to their doctors about current screening and diagnostic options. miRNA panels are still experimental and require further large-scale studies to confirm their accuracy and usefulness in practice.
